A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer

Endocrine-Related Cancer

Volumn 18, Issue 3, 2011, Pages

  Petit, Thierry ^a   Dufour, Patrick ^a   Tannock, Ian ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Princess Margaret Hospital and University of Toronto   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; PRESCRIPTION DRUG; TAMOXIFEN;

ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; EVIDENCE BASED PRACTICE; HUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960100081     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0162     Document Type: Review

References (55)

1. Agrawal K, Onami S, Mortimer JE & Pal SK 2010 Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67 209-214. (doi:10.1016/j.maturitas.2010.07.004)
2. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG & Sahmoud T 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139. (doi:10.1016/S0140-6736(02)09088-8)
3. Beatson GT 1896 On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2 104-107. (doi:10.1016/S0140-6736(01)72307-0)
4. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens RJ et al. 2009 Disease related outcome with long-term follow-up: an updated analysis of the Intergroup Exemestane study. Cancer Research 69 (Suppl 1) Abstract 12. (doi:10.1158/0008-5472.SABCS-09-12)
5. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C et al. 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Annals of Oncology 17 10-14. (doi:10.1093/annonc/mdl941)
6. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A & Steinberg M 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 2247-2258. (doi:10.1002/1097-0142(20011101)92:9〈2247:: AID-CNCR1570〉3.0.CO;2-Y)
7. Brock RC 1952 The Life and Work of Astley Cooper. Edinburgh and London, UK: E&S Livingstone, Ltd.
8. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 25 486-492. (doi:10.1200/JCO.2006. 08.8617)
9. Cole MP, Jones CT & Todd ID 1971 A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 25 270-275. (doi:10.1038/bjc.1971.33)
10. Colleoni M & Giobbie-Hurder A 2010 Benefits and adverse effects of endocrine therapy. Annals of Oncology 21 (Suppl 7) 107-111. (doi:10.1093/annonc/ mdq281)
11. Collins B, Mackenzie J, Stewart A, Bielajew C & Verma S 2009 Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 18 811-821. (doi:10.1002/pon.1453)
12. Conte P & Frassoldati A 2007 Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast Journal 13 28-35. (doi:10.1111/j.1524-4741.2006. 00359.x)
13. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 559-570. (doi:10.1016/S0140-6736(07)60200-1)
14. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M & Forbes JF 2010 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology 11 1135-1141. (doi:10.1016/S1470-2045(10)70257-6)
15. Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M & Mauriac L 2007 Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Cancer 109 2197-2204. (doi:10.1002/cncr.22667)
16. Diab S 2005 Aromatase inhibitors are unlikely to improve overall survival in elderly patients with breast cancer. Breast Cancer Research and Treatment 94 (Suppl 1) abstract 5100 S242.
17. Dodds EC 1948 Oestrogens in the treatment of cancer. Postgraduate Medical Journal 24 295-298. (doi:10.1136/pgmj.24.272.295)
18. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M et al. 2010a Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 28 509-518. (doi:10.1200/JCO.2009.23.1274)
19. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A et al. 2010b Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer patients treated with anastrozole or tamoxifen: a Trans ATAC study. Journal of Clinical Oncology 28 1829-1834. (doi:10.1200/JCO.2009.24.4798)
20. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467. (doi:10.1016/S0140-6736(97)11423-4)
21. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS & Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53. (doi:10.1016/S1470-2045(07)70385-6)
22. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 97 1262-1271. (doi:10.1093/jnci/dji250)
23. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI et al. 2008 Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology 26 1948-1955. (doi:10.1200/JCO.2007.11.6798)
24. Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L & Pritchard KI 2010 Final analysis of NCIC CTG MA.27: a randomized phase III trail of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. Breast Cancer Research and Treatment 94 (Supplement 1) abstract S1.
25. Hadji P 2008 Menopausal symptoms and adjuvant therapy-associated adverse events. Endocrine-Related Cancer 15 73-90. (doi:10.1677/ERC-07-0193)
26. Harris JR, Lippman ME, Morrow M & Osborne CK eds. Diseases of the Breast. Philadelphia, PA, USA: Lippincott Williams & Wilkins 2006.
27. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S & Neugut AI 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. Journal of Clinical Oncology 28 4120-4128. (doi:10.1200/JCO.2009.25.9655)
28. Hind D, Ward S, De Nigris E, Simpson E, Carroll C & Wyld L 2007 Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technology Assessment 11 131-134.
29. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY & Tobias JS 2005 Results of the ATAC (Arimidex Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62. (doi:10.1016/S0140-6736(05)74803- 0)
30. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 455-462. (doi:10.1016/S0140-6736(05)67059-6)
31. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F et al. 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute 99 1845-1853. (doi:10.1093/jnci/djm246)
32. Jakesz R, Gnant M, Griel R, Tausch C, Samonigg H, Kwasny W, Kubista E, Stierer M, Luschin G, Rüecklinger E et al. 2009 Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Research 69 (Supplement 1) abstract 14. (doi:10.1158/0008-5472.SABCS-14)
33. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M & Jakesz R 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive earlystage breast cancer: a meta-analysis. Lancet Oncology 7 991-996. (doi:10.1016/S1470-2045(06) 70948-2)
34. Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel J-M, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E et al. 2009 Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Research 69 (Supplement 1) abstract 15. (doi:10.1158/0008-5472.SABCS-15)
35. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I & von Minckwitz G 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. Journal of Clinical Oncology 25 2664-2670. (doi:10.1200/JCO.2006.08.8054)
36. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC & Paszat LF 2010 Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340 1-8. (doi:10.1136/bmj.c693)
37. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C & Gelmon KA 2007 Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals of Oncology 18 45-51. (doi:10.1093/annonc/mdl334)
38. Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J et al. 2008 Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112 1437-1444. (doi:10.1002/cncr.23320)
39. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN et al. 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of Clinical Oncology 26 1965-1971. (doi:10.1200/JCO.2007.14.0228)
40. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F et al. 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 21 2101-2109. (doi:10.1200/JCO.2003.04.194)
41. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine 361 766-776. (doi:10.1056/NEJMoa0810818)
42. Nordenskjöld B, Rosell J, Rutqvist LE, Malmström PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A & Carstensen J 2005 Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. Journal of the National Cancer Institute 97 1609-1610. (doi:10.1093/jnci/dji342)
43. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826. (doi:10.1056/NEJMoa041588)
44. Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J & Therasse P 2008 Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology 26 4883-4890. (doi:10.1200/JCO.2007.14.4659)
45. Peto R & on behalf of the ATLAS Collaboration 2007 ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Breast Cancer Research and Treatment 106 (Supplement 1) abstract 48 S5.
46. Punglia RS, Burstein HJ, Winer EP & Weeks JC 2008 Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. Journal of the National Cancer Institute 100 642-648. (doi:10.1093/jnci/djn100)
47. Santen RJ & Harvey HA 1999 Use of aromatase inhibitors in breast carcinoma. Endocrine-Related Cancer 6 75-92. (doi:10.1677/erc.0.0060075)
48. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B et al. 2003 Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. Journal of Clinical Oncology 21 984-990. (doi:10.1200/JCO.2003.01.138)
49. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Journal of the American Medical Association 302 1429-1436. (doi:10.1001/jama. 2009.1420)
50. Seruga B & Tannock IF 2009 Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. Journal of Clinical Oncology 27 840-842. (doi:10.1200/JCO.2008.19.5594)
51. Smith IE & Dowsett M 2003 Aromatase inhibitors in breast cancer. New England Journal of Medicine 348 2431-2442. (doi:10.1056/NEJMra023246)
52. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 2747-2757. (doi:10.1056/ NEJMoa052258)
53. Van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET et al. 2011 Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377 321-331. (doi:10.1016/S0140-6736(10)62312-4)
54. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C et al. 2008 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Journal of Clinical Oncology 26 5569-5575. (doi:10.1200/JCO.2008.17. 0829)
55. Viale G, Regan MM, Dell'orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, Macgrogan G, Forbes JF, Paridaens RJ, Colleoni M et al. 2011 Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology [in press]. (doi:10.1093/annonc/mdq738)